Delivery Order SPE2DB22D3102-SPE2DB25FL3DD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Zepbound 2.5 mg/0.5 ml pen injections, with a ceiling value of $1,143.87. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is scheduled for ultimate completion by September 19, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with a ceiling value of $1,143.89. This competitive award, with no set-aside designation, is issued under a firm fixed-price delivery order contract type and is scheduled for completion by August 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $4,275.96 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors. This firm fixed price delivery order, which is scheduled for completion by September 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,525.88 on April 24, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of April 25, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. The contract represents a firm fixed price delivery order with an ultimate completion date of August 15, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,538.71 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injectors on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $27,370.16 on August 8, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors under a firm fixed-price contract. The award was competitively procured with no set-aside designation and is scheduled for completion by August 11, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the...
- The Defense Logistics Agency awarded a delivery order valued at $6,139.84 to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 7, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB25FL3DDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Zepbound 15 mg/0.5 mL pen injectors with a ceiling value of $1,525.16 and an ultimate completion date of September 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. Zepbound is a GLP-1 receptor agonist injectable medication used for weight management, reflecting the company's role in providing specialized pharmaceutical commodities across multiple therapeutic domains to the Defense Health Agency and other government healthcare systems through the DLA's comprehensive global pharmaceutical support vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/18/25 |